Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Implementation of the I-DECIDED tool for PIVC assessment and decision making: discussion paper.
Br J Nurs
January 2025
Postgraduate Program in Nursing, Nursing Department, Health Sciences Centre, Universidade Federal de Santa Catarina, Florianopolis, Brazil.
Highlights: PIVCs often cause pain, irritation, or infection. Regular and careful catheter checks can decrease complications and improve patient outcomes. Implementation of the I-DECIDED® tool led to fewer idle catheters and complications.
View Article and Find Full Text PDFBackground: The burden of hospital-acquired infections (HAIs) equates to 3.5 million cases, resulting in more than 90 000 deaths and 2.5 million disability-adjusted life years (DALYs) across Europe.
View Article and Find Full Text PDFA multimodal approach to reduce the incidence of peripheral venous cannula bacteraemias and improve patient safety.
Br J Nurs
January 2025
Audit and Surveillance Specialist Nurse, Infection Prevention and Control, Royal Devon University Healthcare NHS Foundation Trust.
Background: Incidence of peripheral venous cannula (PVC) bacteraemia have been rising in a trust in the south-west of England, with a 267% increase noted over the 2022/23 financial year compared with the previous year.
Aim: To use a multimodal approach to reduce the incidence of PVC bacteraemia and improve patient safety.
Methods: The initiative consisted of an educational poster highlighting the severity of infection associated with PVCs alongside key prevention messages rooted in Trust policy.
Evaluation of Biodentine® and Calcium Hydroxide in the Formation of Dentin Bridge in Deep Carious Lesions.
West Afr J Med
September 2024
.Department of Preventive Dentistry, Lagos State University, College of Medicine, Faculty of Dentistry, Ikeja, Lagos, PMB 21266, Nigeria.
Background: Indirect pulp capping is the main treatment modality for reversible pulpitis.
Objective: To evaluate the efficacy of Biodentine® and Calcium hydroxide in the formation of dentin bridge.
Materials And Methods: A double blinded, randomized clinical control trial involving 50 consenting subjects, aged 16 to 55 years with deep carious vital teeth.
Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS.
Inflamm Bowel Dis
January 2025
Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Background: Fecal microbiota, live-jslm (RBL; REBYOTA®), is the first single-dose, broad consortia, microbiota-based live biotherapeutic approved by the US Food and Drug Administration to prevent recurrent Clostridioides difficile infection (rCDI) in adults following standard-of-care antimicrobials. Inflammatory bowel disease (IBD) is a common risk factor for rCDI, yet patients with IBD are often excluded from prospective trials. This subgroup analysis of PUNCH CD3-OLS (NCT03931941) evaluated the safety and efficacy of RBL in participants with rCDI and IBD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!